Inhibition of P-glycoprotein activity in human leukemic cells by mifepristone

Anti-Cancer Drugs

Volumn 7, Issue 6, 1996, Pages 671-677

  Fardel, Olivier ^a,b   Courtois, Arnaud ^a   Drenou, Bernard ^b   Lamy, Thierry ^b   Lecureur, Valérie ^a   Le Prisé, Pierre Yves ^b   Fauchet, Renée ^b  

^a Institute de Chimie de'Rennes   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Anti cancer drugs; Leukemic cells; Mifepristone; Multidrug resistance; P glycoprotein

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; MIFEPRISTONE; RHODAMINE 123; VERAPAMIL;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; HORMONE ANTAGONISTS; HUMANS; LEUKEMIA; MIFEPRISTONE; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0029970795     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199608000-00008     Document Type: Article

References (28)

1. Gottesman MM, Pastan I. Biochemistry of MDR mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
2. Van der Bliek AM, Borst P. Multidrug resistance. Adv Cancer Res 1989; 52: 165-263.
3. Bellamy WT, Dalton WS. Multidrug resistance in the laboratory and clinic. Adv Clin Chem 1994; 31: 1-61.
4. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 1976; 455: 155-62.
5. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancer. J Natl Cancer Inst 1989; 81: 116-24.
6. Nooter K, Herweijer H. Multidrug resistance (mdr) in human cancer. Br J Cancer 1991; 63: 663-9.
7. Drenou B, Fardel O, Amiot L, et al. Detection of P-glycoprotein activity in normal and leukemic CD34 positive cells. Leukemia Res 1993; 17: 1031-5.
8. Goasguen JE, Dossot J-M, Fardel O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394-8.
9. Yuen AR, Sikic BI. Multidrug resistance in lymphomas. J Clin Oncol 1994; 12: 2453-9.
10. Lamy T, Drenou B, Grulois I, et al. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia 1995; 9: 1549-55.
11. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 58: 137-71.
12. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993; 11: 1629-35.
13. Salmon SE, Dalton WS, Grogan TM, et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78: 44-50.
14. Sonneveld P, Durie BGM, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992; 340: 255-9.
15. Lecureur V, Fardel O, Guillouzo A. The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett 1994; 355: 187-50.
16. Gruol DJ, Zee MC, Trooter J, et al. Reversal of multidrug resistance by RU 486. Cancer Res 1994; 54: 3088-91.
17. + cases. Blood 1995; 86: 2329-42.
18. Koeffler HP, Billing R, Lusis AJ, et al. An undifferentiated variant derived from the human acute myelogenous leukemia cell line KG1. Blood 1980, 56; 265-73.
19. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45: 321-34.
20. Fardel O, Escande F, Drenou B, et al. Expression of P-glycoprotein in multidrug-resistant human leukemia K562 cells during erythroid differentiation. Int J Oncol 1995; 7: 377-81.
21. Ludescher C, Thaler J, Drach D, et al. Detection of activity of P-glycoprotein in human tumor samples using rhodamine 123. Br J Hematol 1992; 82: 161-8.
22. Noonan KE, Beck C, Holtmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction, Proc Natl Acad Sci USA 1990; 87: 7160-4.
23. Chirgwin JM, Przybyla EA, MacDonald RJ, et al. Isolation of biologically active ribonucleic acids from sources enriched in ribonuclease. Biochemistry 1979; 18: 5294-9.
24. Carmichael J, DcGraff WG, Gazdar AF, et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-42.
25. Neyfakh AA. Use of fluorescent dyes as molecular probes for the study of multidrug resistance. Exp Cell Res 1988; 174: 168-76.
26. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473-6.
27. + acute myeloid leukemia cells. Blood 1993; 82: 3157-62.
28. Kawai S, Nieman LK, Brandon DD, et al. Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. J Pharmacol Exp Ther 1987; 241: 401-6.